Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Breast 2Thoracic 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Adenoviridae Infections 1

Interventions

Fluorouracil 126Leucovorin 90Oxaliplatin 82Specimen Handling 71Gemcitabine 61Magnetic Resonance Spectroscopy 55Irinotecan 55Biopsy 53Capecitabine 40Bevacizumab 40Radiotherapy 37Cisplatin 34Cetuximab 29Chemotherapy, Adjuvant 28Erlotinib Hydrochloride 26Neoadjuvant Therapy 21dehydroftorafur 20Cyclophosphamide 19Nivolumab 18Sorafenib 17Radiation 17Paclitaxel 17X-Rays 16Doxorubicin 16aldesleukin 14Immunoglobulin G 14Disulfides 14fludarabine 13Folfox protocol 13Carboplatin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Vaccines × Gastrointestinal × Clear all
NCT03384316 2020-09-09

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 18 charts
BreastGastrointestinalGenitourinaryThoracic

Adenoviridae Infections, Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡